No Address Available
affiliation not provided to SSRN
oncological immune checkpoint inhibitors, pre-existing autoimmune disease, immune related adverse events, predisposition, autoimmune, autoinflammatory, Malignant melanoma, renal cell carcinoma, Non-Small Cell Lung Cancer, immunotherapy
Early-stage non-small cell lung cancer, PD-L1 expression, Immunotherapy, inter-tumoural heterogeneity